The News: Nasdaq-listed Chinese biotech BeiGene Ltd. (Beijing) has raised an astounding $903 million after pricing its secondary listing in Hong Kong–the first under new exchange rules–near the top of… Read more »
The News: After decades of prominent failures, hope arose for a drug to slow the progression of Alzheimer’s disease (AD). After heightening expectations recently, Eisai Co. Ltd. (Tokyo) and Biogen… Read more »
The News: Sangamo Therapeutics Inc. (Richmond CA) has acquired TxCell SA (Valbonne FRA) with a view toward utilizing its chimeric antigen receptor (CAR) technology to prevent organ transplant rejections and treat… Read more »
The News: Merck & Co.’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions. On Wednesday… Read more »
The News: Kite Pharma Inc. (El Segundo CA) reportedly will support Gadeta BV (Utrecht NLD) in the development of a new type of CAR T-cell therapy that could be more… Read more »
Well, here we are again, looking back at another massive round of biotech IPOs priced just last week, as the beat goes on and on and… My trusty, hand-held calculator… Read more »
The News: Vertex Pharma CEO Jeffrey Leiden’s move earlier this month to pressure England’s prime minister Theresa May on drug prices seems to have set some wheels in motion. After… Read more »
The News: BioArctic AB, based in Stockholm, said it has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial… Read more »
The News: As the cost of sequencing an individual genome gets lower and more people have access to their genomic data, a question has arisen about data ownership. Namely, who… Read more »
The News: Now that we’ve reached the end of the first half of 2018, there might be some interesting surprises–both good and not-so-good–for those equity investors interested in who’s being… Read more »